M. V. Tornamira

Initially metastatic breast carcinoma has a distinct disease pattern but an equivalent outcome compared with recurrent metastatic breast carcinoma

S. Ropero, A. Jimeno, R. Colomer, 2004, Cancer.

Treatment patterns of adjuvant interferon-α2b for high-risk melanoma: a retrospective study of the Grupo Español Multidisciplinar de Melanoma – Prima study

J. Malvehy, V. Guillem, E. Espinosa, 2016, Melanoma research.

Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial.

A. Tres, J. Mayordomo, V. Guillem, 2001, Journal of the National Cancer Institute.

Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study

P. Gascón, J. Feliu, V. Calvo, 2015, Supportive Care in Cancer.

Randomized comparison of broad spectrum antibiotics with or without filgrastim in the treatment of patients with high-risk fever and grade IV neutropenia

J. Mayordomo, V. Guillem, L. Paz-Ares, 1999 .

High‐dose mitoxantrone and cyclophosphamide without stem cell support in patients with high‐risk and advanced breast carcinoma

E. Esteban, J. Pérez-Gracia, R. Colomer, 2001 .